Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:CBPONASDAQ:REPLNASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.57-2.5%$1.74$1.23▼$3.78$349.80M0.993.21 million shs1.58 million shsCBPOChina Biologic Products$119.99$119.23$99.74▼$120.05$4.72B0.47148,695 shs390,921 shsREPLReplimune Group$9.06+2.6%$10.44$4.92▼$17.00$697.76M1.26867,366 shs443,601 shsSWTXSpringWorks Therapeutics$44.93+9.0%$46.68$28.21▼$62.00$3.37B0.791.44 million shs8.84 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+1.26%+15.00%-4.17%-14.36%-52.23%CBPOChina Biologic Products0.00%0.00%0.00%0.00%0.00%REPLReplimune Group+1.61%+15.99%-19.91%-35.64%+37.85%SWTXSpringWorks Therapeutics+1.89%+9.35%-14.93%+14.19%-6.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics2.964 of 5 stars3.53.00.00.01.94.20.6CBPOChina Biologic ProductsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group3.7504 of 5 stars3.60.00.04.53.51.70.6SWTXSpringWorks Therapeutics2.397 of 5 stars3.52.00.00.04.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$9.29491.65% UpsideCBPOChina Biologic Products 0.00N/AN/AN/AREPLReplimune Group 3.13Buy$19.43114.44% UpsideSWTXSpringWorks Therapeutics 3.00Buy$73.2062.92% UpsideCurrent Analyst Ratings BreakdownLatest SWTX, CBPO, REPL, and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025ALLOAllogene TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.003/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.003/14/2025ALLOAllogene TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.002/21/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00 ➝ $74.002/20/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$81.002/13/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.002/12/2025SWTXSpringWorks TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.002/12/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00 ➝ $74.002/10/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$77.00 ➝ $77.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K15,504.82N/AN/A$3.04 per share0.52CBPOChina Biologic Products$503.70M9.38$5.01 per share23.93$45.09 per share2.66REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ASWTXSpringWorks Therapeutics$191.59M17.57N/AN/A$10.01 per share4.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.33N/AN/AN/AN/A-52.13%-41.29%5/12/2025 (Estimated)CBPOChina Biologic Products$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/AREPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)SWTXSpringWorks Therapeutics-$325.10M-$3.48N/AN/AN/A-134.73%-46.74%-41.12%5/1/2025 (Estimated)Latest SWTX, CBPO, REPL, and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q4 2025REPLReplimune Group-$0.75N/AN/AN/AN/AN/A5/12/2025Q1 2025ALLOAllogene Therapeutics-$0.28N/AN/AN/A$0.00 millionN/A5/1/2025Q1 2025SWTXSpringWorks Therapeutics-$0.79N/AN/AN/A$66.93 millionN/A3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A2/20/2025Q4 2024SWTXSpringWorks Therapeutics-$0.66-$1.04-$0.38-$1.04$60.53 million$61.55 million2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACBPOChina Biologic ProductsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35CBPOChina Biologic ProductsN/A12.0110.13REPLReplimune Group0.1411.4311.43SWTXSpringWorks TherapeuticsN/A6.166.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CBPOChina Biologic Products34.77%REPLReplimune Group92.53%SWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics24.30%CBPOChina Biologic Products2.73%REPLReplimune Group8.80%SWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310217.27 million158.72 millionOptionableCBPOChina Biologic Products2,26939.36 millionN/AOptionableREPLReplimune Group21077.02 million70.24 millionOptionableSWTXSpringWorks Therapeutics23074.94 million68.73 millionOptionableSWTX, CBPO, REPL, and ALLO HeadlinesRecent News About These CompaniesGermany's Merck nears roughly $3.5 billion deal for SpringWorks, WSJ reportsApril 24 at 3:20 PM | reuters.comGermany's Merck Nears Roughly $3.5 Billion Deal for SpringWorksApril 24 at 3:05 PM | wsj.comSpringWorks EU approval would enhance strategic value, says EvercoreApril 23 at 6:40 PM | markets.businessinsider.comPositive opinion for Ogsiveo would de-risk SpringWorks deal, says BarclaysApril 23 at 6:40 PM | markets.businessinsider.comRock Springs Capital Management LP Purchases 129,056 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 23 at 6:56 AM | marketbeat.comCapital International Investors Purchases 1,136,079 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 22 at 5:01 AM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by Invesco Ltd.April 21 at 3:32 AM | marketbeat.comWells Fargo & Company MN Has $5.71 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 21 at 3:22 AM | marketbeat.comSpringWorks Therapeutics Target of Unusually High Options Trading (NASDAQ:SWTX)April 18, 2025 | marketbeat.comRussell Investments Group Ltd. Trims Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 18, 2025 | marketbeat.comSpringworks Therapeutics (SWTX) Receives a Buy from Bank of America SecuritiesApril 18, 2025 | markets.businessinsider.comSpringWorks Therapeutics price target lowered to $84 from $87 at BofAApril 17, 2025 | markets.businessinsider.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Holdings Trimmed by Alliancebernstein L.P.April 17, 2025 | marketbeat.comJPMorgan Chase & Co. Sells 27,117 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 17, 2025 | marketbeat.comHere's Why We're Not At All Concerned With SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn SituationApril 13, 2025 | finance.yahoo.comFirst Week of SWTX May 30th Options TradingApril 13, 2025 | nasdaq.comFmr LLC Raises Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 12, 2025 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 7.1% - Here's WhyApril 11, 2025 | marketbeat.comNorges Bank Invests $6.74 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 11, 2025 | marketbeat.comFinepoint Capital LP Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 8, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Sells 50,547 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)April 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialDelta, Walmart Cut Profit Targets: Could Start Domino EffectBy Thomas Hughes | April 10, 2025View Delta, Walmart Cut Profit Targets: Could Start Domino EffectSWTX, CBPO, REPL, and ALLO Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.57 -0.04 (-2.48%) As of 04:00 PM EasternAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.China Biologic Products NASDAQ:CBPOChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Replimune Group NASDAQ:REPL$9.06 +0.23 (+2.60%) As of 04:00 PM EasternReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.SpringWorks Therapeutics NASDAQ:SWTX$44.93 +3.72 (+9.03%) As of 04:00 PM EasternSpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
